$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

$pbyi Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000143774921025298 Filed on November 04, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$55.36M	$46.25M	$50.75M
YoY Change	5.33%	-8.88%	-9.93%
Cost Of Revenue	$11.90M	$10.28M	$9.943M
YoY Change	8.73%	3.38%	6.12%
Gross Profit	$43.46M	$35.97M	$40.81M
YoY Change	4.43%	-11.87%	-13.13%
Gross Profit Margin	78.51%	77.77%	80.41%
Selling, General & Admin	$22.46M	$26.08M	$29.60M
YoY Change	-21.49%	-11.87%	-5.74%
% of Gross Profit	51.68%	72.52%	72.52%
Research & Development	$14.17M	$18.84M	$23.34M
YoY Change	-41.36%	-19.31%	-22.26%
% of Gross Profit	32.6%	52.37%	57.2%
Depreciation & Amortization	$2.271M	$200.0K	$200.0K
YoY Change	-22.76%	0.0%	0.0%
% of Gross Profit	5.23%	0.56%	0.49%
Operating Expenses	$36.63M	$44.92M	$52.94M
YoY Change	-30.57%	-15.15%	-25.22%
Operating Profit	$6.832M	-$8.954M	-$12.13M
YoY Change	-161.33%	-26.19%	-16.04%
Interest Expense	-$2.705M	$3.121M	$3.627M
YoY Change	-23.8%	-13.95%	18.84%
% of Operating Profit	-39.59%
Other Income/Expense, Net	$119.0K	-$35.68M	-$19.33M
YoY Change	70.0%	84.57%	693.27%
Pretax Income	$4.436M	-$44.64M	-$31.46M
YoY Change	-129.99%	41.87%	86.28%
Income Tax	$212.0K	$37.00K	$0.00
% Of Pretax Income	4.78%
Net Earnings	$4.224M	-$44.67M	-$31.46M
YoY Change	-128.17%	41.98%	86.34%
Net Earnings / Revenue	7.63%	-96.6%	-61.99%
Basic Earnings Per Share		-$1.09	-$0.79
Diluted Earnings Per Share	$103.0K	-$1.09	-$0.79
COMMON SHARES
Basic Shares Outstanding	40.89M	40.81M	39.70M
Diluted Shares Outstanding		40.81M	39.70M

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$82.11M	$87.54M	$109.0M
YoY Change	-12.09%	-19.69%	-1.27%
Cash & Equivalents	$63.13M	$63.90M	$90.10M
Short-Term Investments	$18.98M	$23.60M	$18.90M
Other Short-Term Assets	$447.0K	$451.0K	$3.426M
YoY Change	-87.72%	-86.84%	963.98%
Inventory	$7.109M	$7.206M	$3.100M
Prepaid Expenses	$8.984M	$9.074M
Receivables	$32.53M	$23.80M	$24.60M
Other Receivables	$2.880M	$2.819M	$5.900M
Total Short-Term Assets	$140.0M	$136.9M	$159.8M
YoY Change	-4.19%	-14.32%	5.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.756M	$1.924M	$2.659M
YoY Change	-29.22%	-27.64%	-17.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.665M	$4.670M	$6.100M
YoY Change	-8.53%	-23.44%	-62.11%
Total Long-Term Assets	$86.56M	$89.36M	$101.9M
YoY Change	-11.74%	-12.3%	25.88%
TOTAL ASSETS
Total Short-Term Assets	$140.0M	$136.9M	$159.8M
Total Long-Term Assets	$86.56M	$89.36M	$101.9M
Total Assets	$226.6M	$226.3M	$261.7M
YoY Change	-7.22%	-13.53%	12.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.17M	$20.05M	$12.50M
YoY Change	-7.47%	60.38%	38.03%
Accrued Expenses	$92.58M	$90.78M	$63.47M
YoY Change	50.96%	43.03%	-17.32%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$5.714M
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$109.6M	$116.3M	$118.2M
YoY Change	-4.09%	-1.64%	33.8%
LONG-TERM LIABILITIES
Long-Term Debt	$97.09M	$96.80M	$91.71M
YoY Change	15.55%	5.55%	-2.64%
Other Long-Term Liabilities	$22.35M	$24.15M	$52.20M
YoY Change	-56.93%	-53.74%	61.61%
Total Long-Term Liabilities	$97.09M	$96.80M	$91.71M
YoY Change	15.55%	5.55%	-27.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$109.6M	$116.3M	$118.2M
Total Long-Term Liabilities	$97.09M	$96.80M	$91.71M
Total Liabilities	$229.0M	$237.2M	$262.1M
YoY Change	-8.45%	-9.5%	21.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.367B	-$1.371B
YoY Change	2.18%
Common Stock	$1.364B	$1.360B
YoY Change	2.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.446M	-$10.92M	-$453.0K
YoY Change
Total Liabilities & Shareholders Equity	$226.6M	$226.3M	$261.7M
YoY Change	-7.22%	-13.53%	12.78%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	$4.224M	-$44.67M	-$31.46M
YoY Change	-128.17%	41.98%	86.34%
Depreciation, Depletion And Amortization	$2.271M	$200.0K	$200.0K
YoY Change	-22.76%	0.0%	0.0%
Cash From Operating Activities	-$5.435M	$10.50M	$1.720M
YoY Change	-3.63%	510.35%	-123.53%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$10.00K
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$4.621M	-$4.470M	-$2.570M
YoY Change	-57.41%	73.93%	-106.59%
Cash From Investing Activities	$4.621M	-$4.470M	-$2.580M
YoY Change	463.54%	73.26%	-106.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.000K	-31.93M	50.00K
YoY Change	-110.0%	-63958.0%	-28.57%
NET CHANGE
Cash From Operating Activities	-5.435M	10.50M	1.720M
Cash From Investing Activities	4.621M	-4.470M	-2.580M
Cash From Financing Activities	-2.000K	-31.93M	50.00K
Net Change In Cash	-816.0K	-25.90M	-810.0K
YoY Change	-83.0%	3097.65%	-102.55%
FREE CASH FLOW
Cash From Operating Activities	-$5.435M	$10.50M	$1.720M
Capital Expenditures	$0.00	$0.00	-$10.00K
Free Cash Flow	-$5.435M	$10.50M	$1.730M
YoY Change	-223.8%	506.82%	-123.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40885645
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1000000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40860842
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40860842
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40086387
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40086387
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	0	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	12200000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8000000.0	USD
CY2021Q3	pbyi	Finitelived Intangible Asset Expected Amortization Year Eight FinitelivedIntangibleAssetExpectedAmortizationYearEight	8000000.0	USD
CY2021Q3	pbyi	Finitelived Intangible Asset Expected Amortization Year Seven FinitelivedIntangibleAssetExpectedAmortizationYearSeven	8000000.0	USD
CY2021Q3	pbyi	Finitelived Intangible Asset Expected Amortization Year Six FinitelivedIntangibleAssetExpectedAmortizationYearSix	8000000.0	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	8000000.0	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8000000.0	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	8000000.0	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	8000000.0	USD
	pbyi	Fixed Lease Expense FixedLeaseExpense	3500000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	300000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63947000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85293000	USD
CY2021Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	23596000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8096000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23799000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25543000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	7206000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	3454000	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9074000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11262000	USD
CY2021Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	8850000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	8850000	USD
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	451000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3641000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	136923000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	146139000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14641000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16404000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1924000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2481000	USD
CY2021Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	68129000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	74140000	USD
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3311000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3311000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1359000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1745000	USD
CY2021Q3	us-gaap	Assets Assets	226287000	USD
CY2020Q4	us-gaap	Assets Assets	244220000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	20047000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12076000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	90782000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	61325000	USD
CY2021Q3	pbyi	Accrued Inlicensed Rights Current AccruedInlicensedRightsCurrent	0	USD
CY2020Q4	pbyi	Accrued Inlicensed Rights Current AccruedInlicensedRightsCurrent	20993000	USD
CY2021Q3	pbyi	Post Marketing Commitment Liability Current PostMarketingCommitmentLiabilityCurrent	1978000	USD
CY2020Q4	pbyi	Post Marketing Commitment Liability Current PostMarketingCommitmentLiabilityCurrent	2481000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3454000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3094000	USD
CY2021Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	14286000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	116261000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	114255000	USD
CY2021Q3	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	1212000	USD
CY2020Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	25963000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16911000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19549000	USD
CY2021Q3	pbyi	Postmarketing Commitment Liability Noncurrent PostmarketingCommitmentLiabilityNoncurrent	6023000	USD
CY2020Q4	pbyi	Postmarketing Commitment Liability Noncurrent PostmarketingCommitmentLiabilityNoncurrent	6379000	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	96802000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	84025000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	237209000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	250171000	USD
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1360057000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1331676000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1370981000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1337631000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-10922000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-5951000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	226287000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	244220000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46245000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50754000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	197798000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	172553000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10279000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9943000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	51806000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	28434000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26084000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29598000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	93832000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	89882000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18836000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23344000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57702000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	73490000	USD
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	55199000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	62885000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	203340000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	191806000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8954000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12131000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5542000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19253000	USD
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	13000	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	22000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	147000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	474000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	3121000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	3627000	USD
	us-gaap	Interest Expense InterestExpense	10089000	USD
	us-gaap	Interest Expense InterestExpense	10479000	USD
CY2021Q3	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-24498000	USD
CY2020Q3	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-15855000	USD
	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-9781000	USD
	pbyi	Legal Verdict Expense Credit LegalVerdictExpenseCredit	-16041000	USD
CY2021Q3	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-8146000	USD
CY2020Q3	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	USD
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-8146000	USD
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	71000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	128000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	173000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	298000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-35681000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19332000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-27696000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-31463000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-453000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-5951000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28381000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-33350000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-10922000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	17463000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-25748000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-44635000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31463000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33238000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45001000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	37000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	112000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-44672000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-31463000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-33350000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-45001000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.09
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.14
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.09
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.14
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40813609
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39695444
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40520041
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39473691
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40813609
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39695444
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40520041
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39473691
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-44672000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-31463000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-33350000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-45001000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-65000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-3000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44673000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31464000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33352000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45063000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	29469000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4282000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-44672000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-10922000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	23403000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7565000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	43000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27102000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	45000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	100000000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	8444000	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	8519000	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	-0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1910000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-3000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-65000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-45001000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-453000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-33350000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-45001000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	8327000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7085000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	28381000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	27102000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1000000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-8146000	USD
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	-0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2744000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1759000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3752000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-26000	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-2574000	USD
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-4413000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-3190000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	3103000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7971000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6655000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3713000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	20951000	USD
	us-gaap	Increase Decrease In Deferred Leasing Fees IncreaseDecreaseInDeferredLeasingFees	-0	USD
	us-gaap	Increase Decrease In Deferred Leasing Fees IncreaseDecreaseInDeferredLeasingFees	44000	USD
	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-859000	USD
	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-125000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	26085000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6408000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	38073000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	24430000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	22571000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	57033000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15502000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	22580000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	45000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	98500000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	8444000	USD
	pbyi	Installment Payments To Acquire Intangible Assets InstallmentPaymentsToAcquireIntangibleAssets	20000000	USD
	pbyi	Installment Payments To Acquire Intangible Assets InstallmentPaymentsToAcquireIntangibleAssets	-0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-31929000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	45000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21346000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29033000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	97454000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73210000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	76108000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	102243000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	30000000	USD
	us-gaap	Interest Paid Net InterestPaidNet	7914000	USD
	us-gaap	Interest Paid Net InterestPaidNet	7021000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	84000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	183000	USD
	pbyi	Number Of Subsidiaries NumberOfSubsidiaries	2	pure
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-44700000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-33400000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	26100000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63900000	USD
CY2021Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	23600000	USD
CY2021Q3	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	2000000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Use of Estimates: </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:41pt;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of revenues and expenses for the period presented. Accordingly, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:41pt;">Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8765991000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9533446000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-44672000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-31463000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-33350000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-45001000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40814000
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39695000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40520000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39474000
CY2021Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2020Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40814000
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39695000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40520000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39474000
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.09
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.14
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.09
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.14
CY2021Q3	pbyi	Potential Milestone And Royalty Payments Receivable PotentialMilestoneAndRoyaltyPaymentsReceivable	581300000	USD
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	12200000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	69840000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	USD
CY2021Q3	pbyi	Cash Cash Equivalents And Shortterm Investments Fair Value CashCashEquivalentsAndShorttermInvestmentsFairValue	69838000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	79813000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	-0	USD
CY2020Q4	pbyi	Cash Cash Equivalents And Shortterm Investments Fair Value CashCashEquivalentsAndShorttermInvestmentsFairValue	79813000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Concentration of Risk: </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:41pt;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents, marketable securities, and accounts receivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at <em style="font: inherit;"> September 30, 2021</em>, were approximately $75.9 million. The Company does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-<em style="font: inherit;">1/P</em>-<em style="font: inherit;">1</em> or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:41pt;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its accounts receivables, net and product revenues, net. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on the credit worthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. The Company recorded a recovery of $1.0 million credit loss and $1.0 million as an allowance for credit loss for the periods ended <em style="font: inherit;"> September 30, 2021</em> and <em style="font: inherit;"> December 31, 2020</em>, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:41pt;">The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product and limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:41pt;">The Company relies exclusively on <em style="font: inherit;">third</em> parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those <em style="font: inherit;">third</em> parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company has <em style="font: inherit;">no</em> experience in drug formulation or manufacturing and does <em style="font: inherit;">not</em> intend to establish its own manufacturing facilities. The Company lacks the resources and expertise to formulate or manufacture NERLYNX and other drug candidates. While the drug candidates were being developed by Pfizer, both the drug substance and drug product were manufactured by <em style="font: inherit;">third</em>-party contractors. The Company is using the same <em style="font: inherit;">third</em>-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX. If the Company is unable to continue its relationships with <em style="font: inherit;">one</em> or more of these <em style="font: inherit;">third</em>-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on <em style="font: inherit;">one</em> or more <em style="font: inherit;">third</em>-party contractors to manufacture the commercial supply of drugs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021Q3	pbyi	Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits	75900000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1000000.0	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1000000.0	USD
CY2021Q3	pbyi	Average Incremental Borrowing Rate AverageIncrementalBorrowingRate	0.109	pure
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000.0	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6000000.0	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2000000.0	USD
CY2021Q3	pbyi	Finitelived Intangible Asset Expected Amortization Year Nine FinitelivedIntangibleAssetExpectedAmortizationYearNine	2000000.0	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y6M
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.109	pure
CY2021Q3	pbyi	Trade Accounts Receivable Net Excluding License Revenue Receivable TradeAccountsReceivableNetExcludingLicenseRevenueReceivable	20980000	USD
CY2020Q4	pbyi	Trade Accounts Receivable Net Excluding License Revenue Receivable TradeAccountsReceivableNetExcludingLicenseRevenueReceivable	21515000	USD
CY2021Q3	pbyi	License Revenue Receivable LicenseRevenueReceivable	0	USD
CY2020Q4	pbyi	License Revenue Receivable LicenseRevenueReceivable	2500000	USD
CY2021Q3	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	2819000	USD
CY2020Q4	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	2528000	USD
CY2021Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	23799000	USD
CY2020Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	26543000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	-0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1000000	USD
CY2021Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	23799000	USD
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	25543000	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	1000000.0	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1000000.0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1000000	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	1000000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2021Q3	pbyi	Deposit For Manufacturing Costs Current DepositForManufacturingCostsCurrent	0	USD
CY2020Q4	pbyi	Deposit For Manufacturing Costs Current DepositForManufacturingCostsCurrent	3376000	USD
CY2021Q3	pbyi	Prepaid Cro Services Current PrepaidCROServicesCurrent	975000	USD
CY2020Q4	pbyi	Prepaid Cro Services Current PrepaidCROServicesCurrent	1550000	USD
CY2021Q3	pbyi	Prepaid Other Clinical Development Current PrepaidOtherClinicalDevelopmentCurrent	3585000	USD
CY2020Q4	pbyi	Prepaid Other Clinical Development Current PrepaidOtherClinicalDevelopmentCurrent	2718000	USD
CY2021Q3	us-gaap	Prepaid Insurance PrepaidInsurance	658000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3708000	USD
CY2021Q3	pbyi	Prepaid Professional Fess Current PrepaidProfessionalFessCurrent	1128000	USD
CY2020Q4	pbyi	Prepaid Professional Fess Current PrepaidProfessionalFessCurrent	651000	USD
CY2021Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2728000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2635000	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9074000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11262000	USD
CY2021Q3	pbyi	Prepaid Cro Services Noncurrent PrepaidCROServicesNoncurrent	358000	USD
CY2020Q4	pbyi	Prepaid Cro Services Noncurrent PrepaidCROServicesNoncurrent	518000	USD
CY2021Q3	pbyi	Prepaid Other Clinical Development Expense Noncurrent PrepaidOtherClinicalDevelopmentExpenseNoncurrent	410000	USD
CY2020Q4	pbyi	Prepaid Other Clinical Development Expense Noncurrent PrepaidOtherClinicalDevelopmentExpenseNoncurrent	437000	USD
CY2021Q3	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	591000	USD
CY2020Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	790000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1359000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1745000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	10433000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	13007000	USD
CY2021Q3	us-gaap	Deferred Rent Asset Net Current DeferredRentAssetNetCurrent	195000	USD
CY2020Q4	us-gaap	Deferred Rent Asset Net Current DeferredRentAssetNetCurrent	198000	USD
CY2021Q3	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	256000	USD
CY2020Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	67000	USD
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	451000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3641000	USD
	pbyi	Fixed Lease Expense FixedLeaseExpense	3500000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	300000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	4282000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1352000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5483000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5631000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5805000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5983000	USD
CY2021Q3	pbyi	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	1508000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	25762000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5397000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	20365000	USD
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	100000	USD
	us-gaap	Sublease Income SubleaseIncome	300000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	119000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	481000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	495000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	510000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	525000	USD
CY2021Q3	pbyi	Lessor Operating Lease Payments To Be Received After Year Four LessorOperatingLeasePaymentsToBeReceivedAfterYearFour	134000	USD
CY2021Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	2264000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8630000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8632000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6706000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6151000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1924000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2481000	USD
CY2021Q3	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Depreciation Depreciation	600000	USD
CY2021Q3	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	90000000	USD
CY2020Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	90000000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	21871000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15860000	USD
CY2021Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	68129000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	74140000	USD
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000.0	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6000000.0	USD
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P8Y6M
CY2021Q3	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	57328000	USD
CY2020Q4	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	22724000	USD
CY2021Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7699000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8604000	USD
CY2021Q3	pbyi	Accrued Development Costs AccruedDevelopmentCosts	2969000	USD
CY2020Q4	pbyi	Accrued Development Costs AccruedDevelopmentCosts	3474000	USD
CY2021Q3	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	8281000	USD
CY2020Q4	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	9014000	USD
CY2021Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5054000	USD
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	7788000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4374000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4820000	USD
CY2021Q3	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	1277000	USD
CY2020Q4	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	1904000	USD
CY2021Q3	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	1926000	USD
CY2020Q4	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	1420000	USD
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	919000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	383000	USD
CY2021Q3	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	376000	USD
CY2020Q4	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	752000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	579000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	442000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	90782000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	61325000	USD
CY2021Q3	pbyi	Accrued Legal Verdict Expense Noncurrent AccruedLegalVerdictExpenseNoncurrent	0	USD
CY2020Q4	pbyi	Accrued Legal Verdict Expense Noncurrent AccruedLegalVerdictExpenseNoncurrent	24822000	USD
CY2021Q3	pbyi	Accrued Clinical Research Organization Services Noncurrent AccruedClinicalResearchOrganizationServicesNoncurrent	1006000	USD
CY2020Q4	pbyi	Accrued Clinical Research Organization Services Noncurrent AccruedClinicalResearchOrganizationServicesNoncurrent	908000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	206000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	233000	USD
CY2021Q3	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	1212000	USD
CY2020Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	25963000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	91994000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	87288000	USD
CY2021Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	102000000	USD
CY2021Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	5198000	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	96802000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	33997000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	45329000	USD
CY2021Q3	pbyi	Long Term Debt Maturities Repayments Of Principal After Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour	22674000	USD
CY2021Q3	us-gaap	Long Term Debt LongTermDebt	102000000	USD
CY2021Q3	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	212000	USD
CY2020Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	3666000	USD
CY2021Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	5198000	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	5002000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1500000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1400000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	12000
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2011Q4	pbyi	Ordinary Shares Ownership Percentage OrdinarySharesOwnershipPercentage	0.20	pure
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4282000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7565000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28381000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27102000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5009342
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	71.42
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3458000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	640748
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.12
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	148051
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.16
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	744256
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	84.47
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4757783
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	63.13
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1079000	USD
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	949366
CY2021Q3	pbyi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice	10.67
CY2021Q3	pbyi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue	0	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3808417
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	76.21
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1079000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.90
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.81
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	899672
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	8.71
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	640748
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.90
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	148051
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	8.32
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	443003
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	9.52
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	949366
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	7.85
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1300000	USD
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1100000	USD
CY2021Q3	pbyi	Milestone Payments Maximum Amount MilestonePaymentsMaximumAmount	187500000	USD
	pbyi	Percentage Of Unpaid Portion Of Milestone Payments Interest Rate PercentageOfUnpaidPortionOfMilestonePaymentsInterestRate	0.0625	pure
CY2021Q3	pbyi	Milestone Payment MilestonePayment	1800000	USD

Files In Submission

Name	View Source	Status
0001437749-21-025298-index-headers.html	Edgar Link	pending
0001437749-21-025298-index.html	Edgar Link	pending
0001437749-21-025298.txt	Edgar Link	pending
0001437749-21-025298-xbrl.zip	Edgar Link	pending
ex_287369.htm	Edgar Link	pending
ex_287370.htm	Edgar Link	pending
ex_287371.htm	Edgar Link	pending
ex_287372.htm	Edgar Link	pending
ex_301580.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbyi-20210930.xsd	Edgar Link	pending
pbyi-20210930_cal.xml	Edgar Link	unprocessable
pbyi-20210930_def.xml	Edgar Link	unprocessable
pbyi-20210930_lab.xml	Edgar Link	unprocessable
pbyi-20210930_pre.xml	Edgar Link	unprocessable
pbyi20210930_10q.htm	Edgar Link	pending
pbyi20210930_10q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2021 Q4 Form 10-Q Financial Statement

#000143774921025298 Filed on November 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2021 Q4 Form 10-Q Financial Statement

#000143774921025298 Filed on November 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi